Reporting of primary endpoint and associated spin in randomized myeloma trials
The Oncologist · 06.06.2026 · 31 (7)
DOI: 10.1093/oncolo/oyag221 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 02.06.2026. Verfasst von Mitch Singstock und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Utah, Salt Lake City, UT, 84112, United States. Hauptthemen laut MEDLINE: Multiple Myeloma, Randomized Controlled Trials as Topic, Endpoint Determination, Research Design. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Oncology clinical trials, regardless of success in meeting their primary endpoint, often suffer from spin—the misrepresentation of research findings. Despite dramatic improvements in myeloma outcomes, numerous recent myeloma trials have failed to meet their primary endpoints while others have amplified marginally positive findings. A thorough evaluation of reporting practices and spin in myeloma randomized controlled trials (RCTs) is needed. Materials and Methods We performed a cross-sectional analysis of myeloma RCTs that began enrollment in January 2015 or later, with final search conducted in March 2025. Reporting of prespecified primary endpoints and sample size calculations was abstracted. Two reviewers screened for the presence of spin, defined as at least one reporting practice that could mislead readers by emphasizing benefit or minimizing unfavorable findings. Multivariable logistic regression was used to determine factors associated with spin. The methods were registered on the Open Science Framework.
Results
Of 82 screened studies, 71 RCTs were included. The prespecified primary endpoint was statistically significant in 46 trials (64.8%). Sample size calculations were reported in 51 trials (71.8%), and conclusions aligned with primary endpoint results in 63 trials (88.7%). Spin occurred in 25 trials (35.2%), most commonly through optimistic language and emphasis on secondary/subgroup findings. In multivariable analysis, meeting the prespecified primary endpoint was associated with lower odds of spin (adjusted odds ratio [OR] = 0.15; 95% CI, 0.03-0.70; P = .016).
Conclusion
Spin affected one-third of contemporary myeloma RCTs and was strongly associated with nonsignificant primary endpoints, highlighting the need for primary endpoint-aligned interpretation and transparent sample size reporting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Utah, Salt Lake City, UT, 84112, United States.
- Department of Internal Medicine, Mercy Catholic Medical Center, PA, 19023, United States.
- Division of Medical Oncology, University of Colorado Anschutz, Denver, CO, 80045, United States.
- Clinical Research and Evidence Based Medicine Unit, Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece.
- Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, United States.
ORCID-Profile: Mitch Singstock, Abul Hasan Shadali Abdul Khader, Cole Wayant, Mackenzie Lemieux, Maria Mainou, Ghulam Rehman Mohyuddin
Zitieren
APA
Singstock, M., Abdul Khader, A. H. S., Wayant, C., Lemieux, M., Mainou, M., & Mohyuddin, G. R. (2026). Reporting of primary endpoint and associated spin in randomized myeloma trials. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag221
Vancouver
Singstock M, Abdul Khader AHS, Wayant C, Lemieux M, Mainou M, Mohyuddin GR. Reporting of primary endpoint and associated spin in randomized myeloma trials. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag221
BibTeX
@article{Singstock2026,
author = {Singstock, Mitch and Abdul Khader, Abul Hasan Shadali and Wayant, Cole and Lemieux, Mackenzie and Mainou, Maria and Mohyuddin, Ghulam Rehman},
title = {Reporting of primary endpoint and associated spin in randomized myeloma trials},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {7},
doi = {10.1093/oncolo/oyag221}
}
EUVIMED